Detecting Ovarian Cancer References
To ensure the highest quality of content, we use only the latest and most complete primary research the medical community has to offer. All content written and researched by RealAge, Inc., has been peer-reviewed by members of the RealAge Scientific Advisory Board.
References
Aberrant promoter methylation of SPARC in ovarian cancer. Socha, M. J. et al., Neoplasia 2009 Feb:11(2):126-135.
A case-control study of diet and the risk of ovarian cancer. Pan, S. Y. et al.; Canadian Cancer Registries Epidemiology Research Group, Cancer Epidemiology Biomarkers Prevention 2004 Sep;13(9):1521-1527.
Cancer antigen 125 associated with multiple benign and malignant pathologies. Miralles, C. et al., Annals of Surgical Oncology 2003 Mar;10(2):150-154.
Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. McIntosh, M. W. et al., Gynecologic Oncology 2004 Oct;95(1):9-15.
Development of an ovarian cancer symptom index: possibilities for earlier detection. Goff, B. A. et al., Cancer 2007 Jan 15;109(2):221-227.
Diet and ovarian cancer risk: a case-control study in China. Zhang, M. et al., British Journal of Cancer 2002 Mar 4;86(5):712-717.
Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. Goff, B. A. et al., Journal of the American Medical Association 2004 Jun 9;291(22):2705-2712.
Identifying symptoms of ovarian cancer: a qualitative and quantitative study. Bankhead, C. R. et al., BJOG: An International Journal of Obstetrics and Gynaecology 2008 Jul;115(8):1008-1014.
Influence of selected hormonal and lifestyle factors on familial propensity to ovarian cancer. Tavani, A. et al., Gynecologic Oncology 2004 Mar;92(3):922-926.
Ovarian cancer risk after the use of ovulation-stimulating drugs. Brinton, L. A. et al., Obstetrics and Gynecology 2004 Jun;103(6):1194-1203.
Ovarian cancer screening. Urban, N. et al., Hematology/Oncology Clinics of North America 2003 Aug;17(4):989-1005, ix.
Ovarian carcinoma diagnosis. Goff, B. A. et al., Cancer 2000 Nov 15;89(10):2068-2075.
Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California. Mills, P. K. et al., International Journal of Cancer 2004 Nov 10;112(3):458.
Perineal talc use and ovarian cancer: a critical review. Muscat, J. E., Huncharek, M. S., European Journal of Cancer Prevention 2008 Apr;17(2):139-146.
Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Posadas, E. M., Davidson, B., Kohn, E. C., Current Opinion in Oncology 2004 Sep;16(5):478-84.
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Menon, U. et.al., Lancet Oncology 2009 Apr; 10(4):327-340.
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Zhang, Z. et al., Cancer Research 2004 Aug 15;64(16):5882-5890.
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Ibanez de Caceres, I. et al., Cancer Research 2004 Sep 15;64(18):6476-81.
Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. Jensen, A. et al., BMJ 2009 Feb 5; 338:b249.
Use of proteomic patterns in serum to identify ovarian cancer. Petricoin, E. F. et al., Lancet 2002 Feb 16;359(9306):572-577.
